This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An author's correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tenover, F. C.
Right arrow Articles by Hiramatsu, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tenover, F. C.
Right arrow Articles by Hiramatsu, K.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, April 1998, p. 1020-1027, Vol. 36, No. 4
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Characterization of Staphylococci with Reduced Susceptibilities to Vancomycin and Other Glycopeptides

Fred C. Tenover,1,* Michael V. Lancaster,1 Bertha C. Hill,1 Christine D. Steward,1 Sheila A. Stocker,1 Gary A. Hancock,1 Caroline M. O'Hara,1 Nancye C. Clark,1 and Keiichi Hiramatsu2

Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333,1 and Department of Bacteriology, Juntendo University, Tokyo, Japan2

Received 5 December 1997/Returned for modification 18 December 1997/Accepted 30 December 1997

During the last several years a series of staphylococcal isolates that demonstrated reduced susceptibility to vancomycin or other glycopeptides have been reported. We selected 12 isolates of staphylococci for which the vancomycin MICs were >= 4 µg/ml or for which the teicoplanin MICs were >= 8 µg/ml and 24 control strains for which the vancomycin MICs were <= 2 µg/ml or for which the teicoplanin MICs were <= 4 µg/ml to determine the ability of commercial susceptibility testing procedures and vancomycin agar screening methods to detect isolates with reduced glycopeptide susceptibility. By PCR analysis, none of the isolates with decreased glycopeptide susceptibility contained known vancomycin resistance genes. Broth microdilution tests held a full 24 h were best at detecting strains with reduced glycopeptide susceptibility. Disk diffusion did not differentiate the strains inhibited by 8 µg of vancomycin per ml from more susceptible isolates. Most of the isolates with reduced glycopeptide susceptibility were recognized by MicroScan conventional panels and Etest vancomycin strips. Sensititre panels read visually were more variable, although with some of the panels MICs of 8 µg/ml were noted for these isolates. Vitek results were 4 µg/ml for all strains for which the vancomycin MICs were >= 4 µg/ml. Vancomycin MICs on Rapid MicroScan panels were not predictive, giving MICs of either <= 2 or >= 16 µg/ml for these isolates. Commercial brain heart infusion vancomycin agar screening plates containing 6 µg of vancomycin per ml consistently differentiated those strains inhibited by 8 µg/ml from more susceptible strains. Vancomycin-containing media prepared in-house showed occasional growth of susceptible strains, Staphylococcus aureus ATCC 29213, and on occasion, Enterococcus faecalis ATCC 29212. Thus, strains of staphylococci with reduced susceptibility to glycopeptides, such as vancomycin, are best detected in the laboratory by nonautomated quantitative tests incubated for a full 24 h. Furthermore, it appears that commercial vancomycin agar screening plates can be used to detect these isolates.

* Corresponding author. Mailing address: Nosocomial Pathogens Laboratory Branch (G08), Hospital Infections Program, Centers for Disease Control and Prevention, 1600 Clifton Rd., Atlanta, GA 30333. Phone (404) 639-3246. Fax: (404) 639-1381. E-mail: fnt1{at}CDC.GOV.

Journal of Clinical Microbiology, April 1998, p. 1020-1027, Vol. 36, No. 4
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Leonard, S. N., Vidaillac, C., Rybak, M. J. (2009). Activity of Telavancin against Staphylococcus aureus Strains with Various Vancomycin Susceptibilities in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother. 53: 2928-2933 [Abstract] [Full Text]  
  • Swenson, J. M., Anderson, K. F., Lonsway, D. R., Thompson, A., McAllister, S. K., Limbago, B. M., Carey, R. B., Tenover, F. C., Patel, J. B. (2009). Accuracy of Commercial and Reference Susceptibility Testing Methods for Detecting Vancomycin-Intermediate Staphylococcus aureus. J. Clin. Microbiol. 47: 2013-2017 [Abstract] [Full Text]  
  • Renzoni, A., Kelley, W. L., Barras, C., Monod, A., Huggler, E., Francois, P., Schrenzel, J., Studer, R., Vaudaux, P., Lew, D. P. (2009). Identification by Genomic and Genetic Analysis of Two New Genes Playing a Key Role in Intermediate Glycopeptide Resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 903-911 [Abstract] [Full Text]  
  • Hawkey, P. M. (2008). Pre-clinical experience with daptomycin. J Antimicrob Chemother 62: iii7-iii14 [Abstract] [Full Text]  
  • Yusof, A., Engelhardt, A., Karlsson, A., Bylund, L., Vidh, P., Mills, K., Wootton, M., Walsh, T. R. (2008). Evaluation of a New Etest Vancomycin-Teicoplanin Strip for Detection of Glycopeptide-Intermediate Staphylococcus aureus (GISA), in Particular, Heterogeneous GISA. J. Clin. Microbiol. 46: 3042-3047 [Abstract] [Full Text]  
  • Noto, M. J., Fox, P. M., Archer, G. L. (2008). Spontaneous Deletion of the Methicillin Resistance Determinant, mecA, Partially Compensates for the Fitness Cost Associated with High-Level Vancomycin Resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 52: 1221-1229 [Abstract] [Full Text]  
  • Amiali, N. M., Mulvey, M. R., Berger-Bachi, B., Sedman, J., Simor, A. E., Ismail, A. A. (2008). Evaluation of Fourier transform infrared spectroscopy for the rapid identification of glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother 61: 95-102 [Abstract] [Full Text]  
  • Bogdanovich, T., Clark, C., Kosowska-Shick, K., Dewasse, B., McGhee, P., Appelbaum, P. C. (2007). Antistaphylococcal Activity of CG400549, a New Experimental FabI Inhibitor, Compared with That of Other Agents. Antimicrob. Agents Chemother. 51: 4191-4195 [Abstract] [Full Text]  
  • Fitzgibbon, M. M., Rossney, A. S., O'Connell, B. (2007). Investigation of Reduced Susceptibility to Glycopeptides among Methicillin-Resistant Staphylococcus aureus Isolates from Patients in Ireland and Evaluation of Agar Screening Methods for Detection of Heterogeneously Glycopeptide-Intermediate S. aureus. J. Clin. Microbiol. 45: 3263-3269 [Abstract] [Full Text]  
  • Fox, P. M., Climo, M. W., Archer, G. L. (2007). Lack of Relationship between Purine Biosynthesis and Vancomycin Resistance in Staphylococcus aureus: a Cautionary Tale for Microarray Interpretation. Antimicrob. Agents Chemother. 51: 1274-1280 [Abstract] [Full Text]  
  • Wootton, M., MacGowan, A. P., Walsh, T. R., Howe, R. A. (2007). A Multicenter Study Evaluating the Current Strategies for Isolating Staphylococcus aureus Strains with Reduced Susceptibility to Glycopeptides. J. Clin. Microbiol. 45: 329-332 [Abstract] [Full Text]  
  • Nelson, J. L., Rice, K. C., Slater, S. R., Fox, P. M., Archer, G. L., Bayles, K. W., Fey, P. D., Kreiswirth, B. N., Somerville, G. A. (2007). Vancomycin-Intermediate Staphylococcus aureus Strains Have Impaired Acetate Catabolism: Implications for Polysaccharide Intercellular Adhesin Synthesis and Autolysis. Antimicrob. Agents Chemother. 51: 616-622 [Abstract] [Full Text]  
  • Wang, G., Hindler, J. F., Ward, K. W., Bruckner, D. A. (2006). Increased Vancomycin MICs for Staphylococcus aureus Clinical Isolates from a University Hospital during a 5-Year Period. J. Clin. Microbiol. 44: 3883-3886 [Abstract] [Full Text]  
  • Perichon, B., Courvalin, P. (2006). Synergism between {beta}-Lactams and Glycopeptides against VanA-Type Methicillin-Resistant Staphylococcus aureus and Heterologous Expression of the vanA Operon. Antimicrob. Agents Chemother. 50: 3622-3630 [Abstract] [Full Text]  
  • Robert, J., Bismuth, R., Jarlier, V. (2006). Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J Antimicrob Chemother 57: 506-510 [Abstract] [Full Text]  
  • Fang, C.-T., Shau, W.-Y., Hsueh, P.-R., Chen, Y.-C., Wang, J.-T., Hung, C.-C., Huang, L. Y. L., Chang, S.-C. (2006). Early empirical glycopeptide therapy for patients with methicillin-resistant Staphylococcus aureus bacteraemia: impact on the outcome. J Antimicrob Chemother 57: 511-519 [Abstract] [Full Text]  
  • Brown, D. F. J., Edwards, D. I., Hawkey, P. M., Morrison, D., Ridgway, G. L., Towner, K. J., Wren, M. W. D., on behalf of the Joint Working Party of the Britis, (2005). Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA). J Antimicrob Chemother 56: 1000-1018 [Abstract] [Full Text]  
  • Wootton, M., Walsh, T. R., MacGowan, A. P. (2005). Evidence for Reduction in Breakpoints Used To Determine Vancomycin Susceptibility in Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 3982-3983 [Full Text]  
  • Boyle-Vavra, S., Ereshefsky, B., Wang, C.-C., Daum, R. S. (2005). Successful Multiresistant Community-Associated Methicillin-Resistant Staphylococcus aureus Lineage from Taipei, Taiwan, That Carries Either the Novel Staphylococcal Chromosome Cassette mec (SCCmec) Type VT or SCCmec Type IV. J. Clin. Microbiol. 43: 4719-4730 [Abstract] [Full Text]  
  • Sancak, B., Ercis, S., Menemenlioglu, D., Colakoglu, S., Hascelik, G. (2005). Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J Antimicrob Chemother 56: 519-523 [Abstract] [Full Text]  
  • Madrigal, A. G., Basuino, L., Chambers, H. F. (2005). Efficacy of Telavancin in a Rabbit Model of Aortic Valve Endocarditis Due to Methicillin-Resistant Staphylococcus aureus or Vancomycin-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 3163-3165 [Abstract] [Full Text]  
  • Kusuma, C. M., Kokai-Kun, J. F. (2005). Comparison of Four Methods for Determining Lysostaphin Susceptibility of Various Strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 3256-3263 [Abstract] [Full Text]  
  • Hanssen, A.-M., Fossum, A., Mikalsen, J., Halvorsen, D. S., Bukholm, G., Sollid, J. U. E. (2005). Dissemination of Community-Acquired Methicillin-Resistant Staphylococcus aureus Clones in Northern Norway: Sequence Types 8 and 80 Predominate. J. Clin. Microbiol. 43: 2118-2124 [Abstract] [Full Text]  
  • Chambers, H. F. (2005). Evaluation of Ceftobiprole in a Rabbit Model of Aortic Valve Endocarditis Due to Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 884-888 [Abstract] [Full Text]  
  • Perichon, B., Courvalin, P. (2004). Heterologous Expression of the Enterococcal vanA Operon in Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 48: 4281-4285 [Abstract] [Full Text]  
  • Tenover, F. C., Weigel, L. M., Appelbaum, P. C., McDougal, L. K., Chaitram, J., McAllister, S., Clark, N., Killgore, G., O'Hara, C. M., Jevitt, L., Patel, J. B., Bozdogan, B. (2004). Vancomycin-Resistant Staphylococcus aureus Isolate from a Patient in Pennsylvania. Antimicrob. Agents Chemother. 48: 275-280 [Abstract] [Full Text]  
  • von Eiff, C., Kokai-Kun, J. F., Becker, K., Peters, G. (2003). In Vitro Activity of Recombinant Lysostaphin against Staphylococcus aureus Isolates from Anterior Nares and Blood. Antimicrob. Agents Chemother. 47: 3613-3615 [Abstract] [Full Text]  
  • McDougal, L. K., Steward, C. D., Killgore, G. E., Chaitram, J. M., McAllister, S. K., Tenover, F. C. (2003). Pulsed-Field Gel Electrophoresis Typing of Oxacillin-Resistant Staphylococcus aureus Isolates from the United States: Establishing a National Database. J. Clin. Microbiol. 41: 5113-5120 [Abstract] [Full Text]  
  • Liu, C., Chambers, H. F. (2003). Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods. Antimicrob. Agents Chemother. 47: 3040-3045 [Full Text]  
  • Vaudaux, P., Francois, P., Bisognano, C., Li, D., Lew, D. P., Schrenzel, J. (2003). Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J Antimicrob Chemother 52: 89-95 [Abstract] [Full Text]  
  • Chaitram, J. M., Jevitt, L. A., Lary, S., Tenover, F. C. (2003). The World Health Organization's External Quality Assurance System Proficiency Testing Program Has Improved the Accuracy of Antimicrobial Susceptibility Testing and Reporting among Participating Laboratories Using NCCLS Methods. J. Clin. Microbiol. 41: 2372-2377 [Abstract] [Full Text]  
  • Cha, R., Grucz, R. G. Jr., Rybak, M. J. (2003). Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms. Antimicrob. Agents Chemother. 47: 1598-1603 [Abstract] [Full Text]  
  • Moore, M. R., Perdreau-Remington, F., Chambers, H. F. (2003). Vancomycin Treatment Failure Associated with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus in a Patient with Endocarditis and in the Rabbit Model of Endocarditis. Antimicrob. Agents Chemother. 47: 1262-1266 [Abstract] [Full Text]  
  • Haroche, J., Morvan, A., Davi, M., Allignet, J., Bimet, F., El Solh, N. (2003). Clonal Diversity among Streptogramin A-Resistant Staphylococcus aureus Isolates Collected in French Hospitals. J. Clin. Microbiol. 41: 586-591 [Abstract] [Full Text]  
  • Cui, L., Ma, X., Sato, K., Okuma, K., Tenover, F. C., Mamizuka, E. M., Gemmell, C. G., Kim, M.-N., Ploy, M.-C., El Solh, N., Ferraz, V., Hiramatsu, K. (2003). Cell Wall Thickening Is a Common Feature of Vancomycin Resistance in Staphylococcus aureus. J. Clin. Microbiol. 41: 5-14 [Abstract] [Full Text]  
  • Arias, C. A., Reyes, J., Zuniga, M., Cortes, L., Cruz, C., Rico, C. L., Panesso, D., on behalf of the Colombian Antimicrobial Resistanc, (2003). Multicentre surveillance of antimicrobial resistance in enterococci and staphylococci from Colombian hospitals, 2001-2002. J Antimicrob Chemother 51: 59-68 [Abstract] [Full Text]  
  • Schaaff, F., Reipert, A., Bierbaum, G. (2002). An Elevated Mutation Frequency Favors Development of Vancomycin Resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 46: 3540-3548 [Abstract] [Full Text]  
  • MacKenzie, F. M., Greig, P., Morrison, D., Edwards, G., Gould, I. M. (2002). Identification and characterization of teicoplanin-intermediate Staphylococcus aureus blood culture isolates in NE Scotland. J Antimicrob Chemother 50: 689-697 [Abstract] [Full Text]  
  • Heym, B., Le Moal, M., Armand-Lefevre, L., Nicolas-Chanoine, M.-H. (2002). Multilocus sequence typing (MLST) shows that the 'Iberian' clone of methicillin-resistant Staphylococcusaureus has spread to France and acquired reduced susceptibility to teicoplanin. J Antimicrob Chemother 50: 323-329 [Abstract] [Full Text]  
  • Denis, O., Nonhoff, C., Byl, B., Knoop, C., Bobin-Dubreux, S., Struelens, M. J. (2002). Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features. J Antimicrob Chemother 50: 383-391 [Abstract] [Full Text]  
  • Srinivasan, A., Dick, J. D., Perl, T. M. (2002). Vancomycin Resistance in Staphylococci. Clin. Microbiol. Rev. 15: 430-438 [Abstract] [Full Text]  
  • Swenson, J. M., Tenover, F. C. (2002). In vitro activity of a new cephalosporin, RWJ-54428, against streptococci, enterococci and staphylococci, including glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother 49: 845-850 [Abstract] [Full Text]  
  • Kim, M.-N., Hwang, S. H., Pyo, Y.-J., Mun, H.-M., Pai, C. H. (2002). Clonal Spread of Staphylococcus aureus Heterogeneously Resistant to Vancomycin in a University Hospital in Korea. J. Clin. Microbiol. 40: 1376-1380 [Abstract] [Full Text]  
  • Werner, G., Cuny, C., Schmitz, F.-J., Witte, W. (2001). Methicillin-Resistant, Quinupristin-Dalfopristin-Resistant Staphylococcus aureus with Reduced Sensitivity to Glycopeptides. J. Clin. Microbiol. 39: 3586-3590 [Abstract] [Full Text]  
  • Walsh, T. R., Bolmstrom, A., Qwarnstrom, A., Ho, P., Wootton, M., Howe, R. A., MacGowan, A. P., Diekema, D. (2001). Evaluation of Current Methods for Detection of Staphylococci with Reduced Susceptibility to Glycopeptides. J. Clin. Microbiol. 39: 2439-2444 [Abstract] [Full Text]  
  • Marlowe, E. M., Cohen, M. D., Hindler, J. F., Ward, K. W., Bruckner, D. A. (2001). Practical Strategies for Detecting and Confirming Vancomycin-Intermediate Staphylococcus aureus: a Tertiary-Care Hospital Laboratory's Experience. J. Clin. Microbiol. 39: 2637-2639 [Abstract] [Full Text]  
  • Aires de Sousa, M., Miragaia, M., Santos Sanches, I., Avila, S., Adamson, I., Casagrande, S. T., Brandileone, M. C. C., Palacio, R., Dell'Acqua, L., Hortal, M., Camou, T., Rossi, A., Velazquez-Meza, M. E., Echaniz-Aviles, G., Solorzano-Santos, F., Heitmann, I., de Lencastre, H. (2001). Three-Year Assessment of Methicillin-Resistant Staphylococcus aureus Clones in Latin America from 1996 to 1998. J. Clin. Microbiol. 39: 2197-2205 [Abstract] [Full Text]  
  • O'Neill, A. J., Cove, J. H., Chopra, I. (2001). Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. J Antimicrob Chemother 47: 647-650 [Abstract] [Full Text]  
  • Chamberland, S., Blais, J., Hoang, M., Dinh, C., Cotter, D., Bond, E., Gannon, C., Park, C., Malouin, F., Dudley, M. N. (2001). In Vitro Activities of RWJ-54428 (MC-02,479) against Multiresistant Gram-Positive Bacteria. Antimicrob. Agents Chemother. 45: 1422-1430 [Abstract] [Full Text]  
  • Climo, M. W., Ehlert, K., Archer, G. L. (2001). Mechanism and Suppression of Lysostaphin Resistance in Oxacillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 1431-1437 [Abstract] [Full Text]  
  • Wootton, M., Howe, R. A., Hillman, R., Walsh, T. R., Bennett, P. M., MacGowan, A. P. (2001). A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 47: 399-403 [Abstract] [Full Text]  
  • Aritaka, N., Hanaki, H., Cui, L., Hiramatsu, K. (2001). Combination Effect of Vancomycin and {beta}-Lactams against a Staphylococcus aureus Strain, Mu3, with Heterogeneous Resistance to Vancomycin. Antimicrob. Agents Chemother. 45: 1292-1294 [Abstract] [Full Text]  
  • Akins, R. L., Rybak, M. J. (2001). Bactericidal Activities of Two Daptomycin Regimens against Clinical Strains of Glycopeptide Intermediate-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus faecium, and Methicillin-Resistant Staphylococcus aureus Isolates in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother. 45: 454-459 [Abstract] [Full Text]  
  • Vaudaux, P., Francois, P., Berger-Bachi, B., Lew, D. P. (2001). In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible, methicillin-resistant strain of Staphylococcus aureus. J Antimicrob Chemother 47: 163-170 [Abstract] [Full Text]  
  • Trakulsomboon, S., Danchaivijitr, S., Rongrungruang, Y., Dhiraputra, C., Susaemgrat, W., Ito, T., Hiramatsu, K. (2001). First Report of Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Thailand. J. Clin. Microbiol. 39: 591-595 [Abstract] [Full Text]  
  • Booth, M. C., Pence, L. M., Mahasreshti, P., Callegan, M. C., Gilmore, M. S. (2001). Clonal Associations among Staphylococcus aureus Isolates from Various Sites of Infection. Infect. Immun. 69: 345-352 [Abstract] [Full Text]  
  • Tenover, F. C., Mohammed, M. J., Stelling, J., O'Brien, T., Williams, R. (2001). Ability of Laboratories To Detect Emerging Antimicrobial Resistance: Proficiency Testing and Quality Control Results from the World Health Organization's External Quality Assurance System for Antimicrobial Susceptibility Testing. J. Clin. Microbiol. 39: 241-250 [Abstract] [Full Text]  
  • Tsakris, A., Papadimitriou, E., Douboyas, J., Antoniadis, A. (2000). Emergence of teicoplanin-resistant Staphylococcus haemolyticus clinical isolates in Greece. J Antimicrob Chemother 46: 1040-1041 [Full Text]  
  • Drew, R. H., Perfect, J. R., Srinath, L., Kurkimilis, E., Dowzicky, M., Talbot, G. H., for the Synercid Emergency-Use Study Group, (2000). Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. J Antimicrob Chemother 46: 775-784 [Abstract] [Full Text]  
  • Aucken, H. M., Warner, M., Ganner, M., Johnson, A. P., Richardson, J. F., Cookson, B. D., Livermore, D. M. (2000). Twenty months of screening for glycopeptide-intermediateStaphylococcus aureus. J Antimicrob Chemother 46: 639-640 [Full Text]  
  • Kim, M.-N., Pai, C. H., Woo, J. H., Ryu, J. S., Hiramatsu, K. (2000). Vancomycin-Intermediate Staphylococcus aureus in Korea. J. Clin. Microbiol. 38: 3879-3881 [Abstract] [Full Text]  
  • Cui, L., Murakami, H., Kuwahara-Arai, K., Hanaki, H., Hiramatsu, K. (2000). Contribution of a Thickened Cell Wall and Its Glutamine Nonamidated Component to the Vancomycin Resistance Expressed by Staphylococcus aureus Mu50. Antimicrob. Agents Chemother. 44: 2276-2285 [Abstract] [Full Text]  
  • Kiehlbauch, J. A., Hannett, G. E., Salfinger, M., Archinal, W., Monserrat, C., Carlyn, C. (2000). Use of the National Committee for Clinical Laboratory Standards Guidelines for Disk Diffusion Susceptibility Testing in New York State Laboratories. J. Clin. Microbiol. 38: 3341-3348 [Abstract] [Full Text]  
  • von Eiff, C., Reinert, R. R., Kresken, M., Brauers, J., Hafner, D. (2000). Nationwide German Multicenter Study on Prevalence of Antibiotic Resistance in Staphylococcal Bloodstream Isolates and Comparative In Vitro Activities of Quinupristin-Dalfopristin. J. Clin. Microbiol. 38: 2819-2823 [Abstract] [Full Text]  
  • Akins, R. L., Rybak, M. J. (2000). In Vitro Activities of Daptomycin, Arbekacin, Vancomycin, and Gentamicin Alone and/or in Combination against Glycopeptide Intermediate-Resistant Staphylococcus aureus in an Infection Model. Antimicrob. Agents Chemother. 44: 1925-1929 [Abstract] [Full Text]  
  • Killgore, G. E., Holloway, B., Tenover, F. C. (2000). A 5' Nuclease PCR (TaqMan) High-Throughput Assay for Detection of the mecA Gene in Staphylococci. J. Clin. Microbiol. 38: 2516-2519 [Abstract] [Full Text]  
  • Chesneau, O., Morvan, A., Solh, N. E. (2000). Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals. J Antimicrob Chemother 45: 887-890 [Abstract] [Full Text]  
  • Heffelfinger, J. D., Dowell, S. F., Jorgensen, J. H., Klugman, K. P., Mabry, L. R., Musher, D. M., Plouffe, J. F., Rakowsky, A., Schuchat, A., Whitney, C. G., and the Drug-Resistant Streptococcus pneumoniae Th, (2000). Management of Community-Acquired Pneumonia in the Era of Pneumococcal Resistance: A Report From the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 160: 1399-1408 [Abstract] [Full Text]  
  • Boyle-Vavra, S., Berke, S. K., Lee, J. C., Daum, R. S. (2000). Reversion of the Glycopeptide Resistance Phenotype in Staphylococcus aureus Clinical Isolates. Antimicrob. Agents Chemother. 44: 272-277 [Abstract] [Full Text]  
  • Pfeltz, R. F., Singh, V. K., Schmidt, J. L., Batten, M. A., Baranyk, C. S., Nadakavukaren, M. J., Jayaswal, R. K., Wilkinson, B. J. (2000). Characterization of Passage-Selected Vancomycin-Resistant Staphylococcus aureus Strains of Diverse Parental Backgrounds. Antimicrob. Agents Chemother. 44: 294-303 [Abstract] [Full Text]  
  • Marchese, A., Balistreri, G., Tonoli, E., Debbia, E. A., Schito, G. C. (2000). Heterogeneous Vancomycin Resistance in Methicillin-Resistant Staphylococcus aureus Strains Isolated in a Large Italian Hospital. J. Clin. Microbiol. 38: 866-869 [Abstract] [Full Text]  
  • Hubert, S. K., Mohammed, J. M., Fridkin, S. K., Gaynes, R. P., McGowan, J. E. Jr., Tenover, F. C. (1999). Glycopeptide-Intermediate Staphylococcus aureus: Evaluation of a Novel Screening Method and Results of a Survey of Selected U.S. Hospitals. J. Clin. Microbiol. 37: 3590-3593 [Abstract] [Full Text]  
  • De Giusti, M., Pacifico, L., Tufi, D., Panero, A., Boccia, A., Chiesa, C. (1999). Phenotypic detection of nosocomial mecA-positive coagulase-negative staphylococci from neonates. J Antimicrob Chemother 44: 351-358 [Abstract] [Full Text]  
  • Howe, R. A., Wootton, M., Bennett, P. M., MacGowan, A. P., Walsh, T. R. (1999). Interactions between Methicillin and Vancomycin in Methicillin-Resistant Staphylococcus aureus Strains Displaying Different Phenotypes of Vancomycin Susceptibility. J. Clin. Microbiol. 37: 3068-3071 [Abstract] [Full Text]  
  • Climo, M. W., Patron, R. L., Archer, G. L. (1999). Combinations of Vancomycin and beta -Lactams Are Synergistic against Staphylococci with Reduced Susceptibilities to Vancomycin. Antimicrob. Agents Chemother. 43: 1747-1753 [Abstract] [Full Text]  
  • Patron, R. L., Climo, M. W., Goldstein, B. P., Archer, G. L. (1999). Lysostaphin Treatment of Experimental Aortic Valve Endocarditis Caused by a Staphylococcus aureus Isolate with Reduced Susceptibility to Vancomycin. Antimicrob. Agents Chemother. 43: 1754-1755 [Abstract] [Full Text]  
  • Callegan, M. C., Booth, M. C., Jett, B. D., Gilmore, M. S. (1999). Pathogenesis of Gram-Positive Bacterial Endophthalmitis. Infect. Immun. 67: 3348-3356 [Abstract] [Full Text]  
  • McKenney, D., Pouliot, K. L., Wang, Y., Murthy, V., Ulrich, M., Döring, G., Lee, J. C., Goldmann, D. A., Pier, G. B. (1999). Broadly Protective Vaccine for Staphylococcus aureus Based on an in Vivo-Expressed Antigen. Science 284: 1523-1527 [Abstract] [Full Text]  
  • Kantzanou, M., Tassios, P. T., Tseleni-Kotsovili, A., Legakis, N. J., Vatopoulos, A. C. (1999). Reduced susceptibility to vancomycin of nosocomial isolates of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 43: 729-731 [Abstract] [Full Text]  
  • Smith, T. L., Pearson, M. L., Wilcox, K. R., Cruz, C., Lancaster, M. V., Robinson-Dunn, B., Tenover, F. C., Zervos, M. J., Band, J. D., White, E., Jarvis, W. R., The Glycopeptide-Intermediate Staphylococcus aureu, (1999). Emergence of Vancomycin Resistance in Staphylococcus aureus. NEJM 340: 493-501 [Abstract] [Full Text]  
  • Sieradzki, K., Roberts, R. B., Haber, S. W., Tomasz, A. (1999). The Development of Vancomycin Resistance in a Patient with Methicillin-Resistant Staphylococcus aureus Infection. NEJM 340: 517-523 [Full Text]  
  • Lowy, F. D. (1998). Staphylococcus aureus Infections. NEJM 339: 520-532 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»